Every material Form 8-K FENNEC PHARMACEUTICALS INC. has filed with the SEC since May 18, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Fennec Pharmaceuticals said detailed results from the investigator-initiated Phase 2 STS-J01 study of PEDMARK in Japan met the primary endpoint, with hearing loss in 24.0% of patients versus a prespecified historical benchmark of 56.4%. The data were presented orally on September 17, 2026, at the 58th SIOP Annual Meeting, and the company said it is pursuing registration in Japan and exploring partnering or licensing options.
Primary endpoint met: ASHA-defined hearing loss in 24.0% (6 of 25) versus a prespecified historical benchmark of 56.4% (P=0.001)
84.0% of patients had Grade 0 hearing loss by Brock criteria; no Grade 3 or Grade 4 hearing loss was observed
Objective tumor responses in 23 of 24 evaluable patients (95.8%)
Results presented at the 58th SIOP Annual Meeting in San Antonio, TX; Fennec is pursuing registration in Japan and exploring partnering or licensing for PEDMARK
Fennec Pharmaceuticals said on May 21, 2026 that new research on PEDMARK across several patient populations and tumor types will be presented at the 2026 American Society of Clinical Oncology Annual Meeting. The filing contains no financial results, guidance, or financial figures, so it is a clinical and research update rather than a measure of company performance.
Four independently led studies will be shared at the ASCO Annual Meeting, covering adolescent, young adult and adult patients as well as pediatric patients.
The Japanese Phase 2/3 STS-J01 study enrolled 27 patients and reported hearing loss of 16-24% with PEDMARK versus 56-63% with cisplatin alone, per the filing's historical comparison.
A randomized Phase 1 trial for men with metastatic germ cell tumors, opened to accrual by City of Hope in January 2026, will present its trial design.
Fennec Pharmaceuticals granted stock options to purchase 50,000 common shares to three new non-executive employees under its 2026 Equity Inducement Plan, with a grant date of May 18, 2026. The options have an exercise price of $9.75 per share and vest over three years, and the filing describes them as inducement awards under Nasdaq Listing Rule 5635(c)(4) for new hires, with no financial effect reported.
Options cover an aggregate of 50,000 common shares granted to three new non-executive employees
Exercise price is $9.75 per share, equal to the closing price on March 15, 2026, with a ten-year term
One-third vests on the one-year anniversary of the May 18, 2026 grant date, then monthly over the following 24 months
Grants include 49,141 incentive stock options and 859 nonqualified stock options
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every FENNEC PHARMACEUTICALS INC. filing is on SEC EDGAR ↗. 8-K briefs of other companies →